HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1.

AbstractBACKGROUND AND PURPOSE:
3',5'-Cyclic nucleotide PDE4 is expressed in several inflammatory and immune cells, and PDE4 catalyses the hydrolysis of cAMP to 5'AMP, down-regulating cAMP signalling in cells. MAPK phosphatase-1 (MKP-1) is an endogenous p38 MAPK signalling suppressor and limits inflammatory gene expression and inflammation. In the present study, we investigated the effect of a PDE4 inhibitor rolipram on MKP-1 expression and whether MKP-1 is involved in the anti-inflammatory effects of rolipram.
EXPERIMENTAL APPROACH:
The effect of rolipram on TNF production was investigated in J774 mouse macrophage cell line and in primary mouse peritoneal macrophages (PM) from wild-type (WT) and MKP-1(-/-) mice. We also investigated the effect of rolipram on carrageenan-induced paw inflammation in WT and MKP-1(-/-) mice.
KEY RESULTS:
MKP-1 expression was enhanced by rolipram, by a non-selective PDE inhibitor IBMX and by a cAMP analogue 8-Br-cAMP in J774 cells and in PM. Enhanced MKP-1 mRNA expression by rolipram was reversed by a PKA inhibitor. Rolipram, IBMX and 8-Br-cAMP also inhibited TNF production in activated macrophages. Accordingly, rolipram inhibited TNF production in PMs from WT mice but, interestingly, not in PMs from MKP-1(-/-) mice. Furthermore, rolipram attenuated carrageenan-induced paw inflammation in WT but not in MKP-1(-/-) mice.
CONCLUSIONS AND IMPLICATIONS:
PDE4 inhibitor rolipram was found to enhance the expression of MKP-1, and MKP-1 mediated, at least partly, the anti-inflammatory effects of PDE4 inhibition. The results suggest that compounds that enhance MKP-1 expression and/or MKP-1 activity hold potential as novel anti-inflammatory drugs.
AuthorsRiku Korhonen, Tuija Hömmö, Tiina Keränen, Mirka Laavola, Mari Hämäläinen, Katriina Vuolteenaho, Lauri Lehtimäki, Hannu Kankaanranta, Eeva Moilanen
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 169 Issue 7 Pg. 1525-36 (Aug 2013) ISSN: 1476-5381 [Electronic] England
PMID23849041 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013 The Authors. British Journal of Pharmacology © 2013 The British Pharmacological Society.
Chemical References
  • Phosphodiesterase 4 Inhibitors
  • Tumor Necrosis Factor-alpha
  • Carrageenan
  • Dual Specificity Phosphatase 1
  • Rolipram
Topics
  • Animals
  • Carrageenan (pharmacology)
  • Cell Line
  • Dual Specificity Phosphatase 1 (physiology)
  • Inflammation (chemically induced, genetics, metabolism)
  • Macrophages (metabolism)
  • Mice
  • Mice, Inbred C57BL
  • Phosphodiesterase 4 Inhibitors (pharmacology)
  • Rolipram (pharmacology)
  • Signal Transduction (drug effects)
  • Tumor Necrosis Factor-alpha (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: